🔬 They will produce RION’s Purified Exosome Product™ (PEP) for late-phase clinical supplies in Houston.
📈 RION’s proprietary platform supports scalable production of exosomes, advancing treatments across various medical fields.
💊 This partnership aims to provide innovative, affordable therapies to patients globally.
Introduction:
The recent collaboration between Lonza and RION marks a significant advancement in the manufacturing of exosome-based therapeutics, specifically designed for clinical applications. This partnership aims to leverage Lonza’s expertise in manufacturing to support RION’s innovative therapeutic pipeline based on their proprietary Purified Exosome Product™ (PEP).
- Lonza will provide cGMP manufacturing and technical support for RION’s PEP drug substance, facilitating commercial-scale production.
- RION’s proprietary biomanufacturing platform enables the large-scale production of platelet-derived exosomes, crucial for advancing their therapeutic pipeline.
- PEP is characterized by its immunomodulatory, anti-inflammatory, and tissue regenerative properties, designed as a stable lyophilized powder.
- The collaboration promises to enhance operational processes at scale, allowing for the rapid delivery of innovative treatments to patients across various indications.
- Clinical programs are being developed in multiple health domains, including tissue regeneration, dermatology, musculoskeletal, pulmonary, cardiovascular, and women’s health.
Conclusion:
This collaboration positions both companies to significantly impact the field of exosome-based therapeutics, ensuring scalable production and accessibility of innovative treatments. The initiative not only emphasizes advancements in biomanufacturing technologies but also holds promise for a broad range of therapeutic applications, aligning with RION’s mission for affordable healthcare solutions.
